Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could tailor CMV prevention after stem cell transplants

NCT ID NCT06453460

Recruiting now Disease control Sponsor: University of California, Irvine Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a blood test that measures CMV-specific immunity (CMV-TCIP) can help doctors decide how long to continue the antiviral drug letermovir after an allogeneic stem cell transplant. Participants receive letermovir for 14 weeks, then the test guides whether to extend prophylaxis. The goal is to prevent clinically significant CMV infection within the first year after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
letermovir, a drug to prevent CMV infection, and a CMV immunity blood test (CMV-TCIP) to guide treatment duration
What this could lead to
If successful, this approach could reduce CMV infections after stem cell transplant while avoiding unnecessary prolonged medication.
What could go wrong
This is a small, early-phase trial, so results may not apply to all patients. The blood test may not accurately predict infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGENEIC STEM CELL TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLOGENEIC STEM CELL TRANSPLANTATION CMV

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Chao Family Comprehensive Cancer Center, University of California Irvine

    RECRUITING

    Orange, California, 92868, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.